Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hefei Hygeiancells Biomedical Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with a focused prosecution strategy. There is currently 1 pending office action associated with the company, representing the current extent of its pending legal challenges at the patent office. MOSS, NATALIE M is the busiest examiner for the company, overseeing this active matter. The company's presence in this sector highlights its specialized role in the biomedical field.
The company's interaction with the USPTO is currently restricted to 1 distinct examiner and a distinct art unit. With MOSS, NATALIE M managing the busiest examiner pending action, the company's immediate patenting trajectory is shaped by the decisions of a single examiner. This narrow scope of prosecution suggests that the company's current intellectual property efforts are not distributed across multiple technical domains or examiner groups. Practitioners should recognize that the outcome of this single pending action will define the company's current success rate within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSS, NATALIE M | 1 | 30.7% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17267586 | Drug Used for Treating Tissue Necrosis or for Improving Cardiac Function | MOSS, NATALIE M | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17267586 | Drug Used for Treating Tissue Necrosis or for Improving Cardiac Function | MOSS, NATALIE M | 13d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17267586 | Drug Used for Treating Tissue Necrosis or for Improving Cardiac Function | MOSS, NATALIE M | 1653 | §103§112 | Final Rejection | 13d | Pending | Feb 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHefei Hygeiancells Biomedical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Natalie M Moss has the most, with 1 of Hefei Hygeiancells Biomedical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
